middle.news
InhaleRx Launches Phase 1 Trial of Rapid-Acting CBD Inhaler for Panic Disorder
2:36am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
InhaleRx Launches Phase 1 Trial of Rapid-Acting CBD Inhaler for Panic Disorder
2:36am on Saturday 30th of August, 2025 AEST
Key Points
HREC approval granted for Phase 1 trial of IRX-616a
Randomised, double-blind, placebo-controlled single ascending dose study
Trial to enrol up to 24 healthy volunteers at CMAX, Adelaide
IRX-616a is a synthetic CBD aerosol delivered via metered-dose inhaler
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inhalerx (ASX:IRX)
OPEN ARTICLE